The nanoscale albumin-bound paclitaxel formulation developed by Celgene Corporation in the United States (Nab-PTX) demonstrates superior anti-tumor effects in GC compared to commonly used anti-tumor drugs 5-fluorouracil (5-FU) and lobaplatin (LBP), with significant disparities observed in its ability to induce autophagy and cell apoptosis (Cheng et al., 2022). This evidence concerns the gene ALB and neoplasm.